No limits: NewLimit lands $435m ahead of human trials
The longevity biotech is accelerating toward the clinic after uncovering a promising age-reprogramming therapy years sooner than expected.…
NewLimit ‘close’ to clinic-ready epigenetic reprogramming therapy
Liver rejuvenation program produces a ‘lead payload’ as biotech begins its journey towards human clinical trials. After several…
Lilly invests in epigenetic reprogramming biotech
NewLimit adds $45m in new funding at a $1.6bn valuation following preclinical progress that brings clinical trials closer…